REGN Regeneron Pharmaceuticals PE ratio, current and historical analysis
As of Mar 18, 2025, the Regeneron Pharmaceuticals stock's PE ratio is 16.26. This takes into account the latest EPS of $40.9 and stock price of $664.96. The PE ratio marks a decrease of 31% from its last 4 quarters average of 23.6.
REGN PE ratio history
The PE ratio of Regeneron Pharmaceuticals has averaged 32.05 over the last ten years. The current P/E ratio of 16.26 is 49% lower than the historical average. Looking back at the last ten years, REGN's PE ratio peaked in the Mar 2015 quarter at 132.01, when the price was $451.48 and the EPS was $3.42. The lowest point was in the Dec 2021 quarter, when it reached 8.27 with a price of $631.52 and an EPS of $76.4.
Regeneron Pharmaceuticals PE ratio by year
Maximum annual increase: 201.25% in 2013
Maximum annual decrease: -51.21% in 2016
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 17.42 | -26.53% | $712.33 | $40.9 |
| 2023 | 23.71 | 33.13% | $878.29 | $37.05 |
| 2022 | 17.81 | 115.36% | $721.49 | $40.51 |
| 2021 | 8.27 | -44.12% | $631.52 | $76.4 |
| 2020 | 14.8 | -23.59% | $483.11 | $32.65 |
| 2019 | 19.37 | 17.47% | $375.48 | $19.38 |
| 2018 | 16.49 | -50.57% | $373.5 | $22.65 |
| 2017 | 33.36 | -22.29% | $375.96 | $11.27 |
| 2016 | 42.93 | -51.21% | $367.09 | $8.55 |
| 2015 | 87.99 | -27.94% | $542.87 | $6.17 |
| 2014 | 122.1 | 87.64% | $410.25 | $3.36 |
| 2013 | 65.07 | 201.25% | $275.24 | $4.23 |
| 2012 | 21.6 | N/A | $171.07 | $7.92 |
| 2011 | N/A | N/A | $55.43 | -$2.45 |
| 2010 | N/A | N/A | $32.83 | -$1.26 |
Regeneron Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 17.42 | -28.34% | $712.33 | $40.9 |
| Sep 2024 | 24.31 | -6.75% | $1,051.24 | $43.24 |
| Jun 2024 | 26.07 | -2.18% | $1,051.03 | $40.32 |
| Mar 2024 | 26.65 | 12.4% | $962.49 | $36.12 |
| Dec 2023 | 23.71 | 7.67% | $878.29 | $37.05 |
| Sep 2023 | 22.02 | 23.22% | $822.96 | $37.38 |
| Jun 2023 | 17.87 | -15.07% | $718.54 | $40.21 |
| Mar 2023 | 21.04 | 18.14% | $821.67 | $39.06 |
| Dec 2022 | 17.81 | 30.09% | $721.49 | $40.51 |
| Sep 2022 | 13.69 | 23.56% | $688.87 | $50.31 |
| Jun 2022 | 11.08 | 19.01% | $591.13 | $53.37 |
| Mar 2022 | 9.31 | 12.58% | $698.42 | $74.98 |
| Dec 2021 | 8.27 | -9.42% | $631.52 | $76.4 |
| Sep 2021 | 9.13 | -3.69% | $605.18 | $66.28 |
| Jun 2021 | 9.48 | -24.7% | $558.54 | $58.89 |
REGN average PE ratio chart
REGN's current PE ratio is lower than its 3, 5 and 10-year averages.
REGN PE vs peers
REGN's PE ratio stands lower than its peer stocks JNJ and NVS, but it is higher than BIIB's. Regeneron Pharmaceuticals is currently trading at a lower PE ratio (16.26) than its peers average of 25.42.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BIIB Biogen Inc | 12.68 | $20.8B |
| REGN Regeneron Pharmaceuticals Inc | 16.29 | $72.83B |
| NVS Novartis AG | 18.84 | $220.24B |
| JNJ Johnson & Johnson | 27.91 | $392.42B |
| AMGN Amgen Inc | 41.51 | $169.93B |
| ALNY Alnylam Pharmaceuticals Inc | N/A | $32.84B |
Frequently asked questions
What is Regeneron Pharmaceuticals's PE ratio?
REGN stock has a price to earnings ratio of 16.26 as of Mar 18, 2025.
What is the 3-year average PE ratio for Regeneron Pharmaceuticals (REGN)?
The 3-year average price to earnings ratio for REGN stock is 19.25.
What is the 5-year average PE ratio for Regeneron Pharmaceuticals (REGN)?
The 5-year average price to earnings ratio for REGN stock is 17.54.
What is the highest PE ratio for REGN?
Over the last ten years, the quarterly PE ratio reached its highest level at 132.01 in the Mar 2015 quarter.
How does the current PE ratio for REGN compare to its historical average?
REGN's price to earnings ratio is currently 49% below its 10-year historical average.
How is REGN's PE ratio calculated (Regeneron Pharmaceuticals PE ratio formula)?
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Mar 18, 2025), Regeneron Pharmaceuticals's share price is $664.96. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $40.9. Therefore, Regeneron Pharmaceuticals's PE ratio for today is 16.26. PE RATIO(16.26) = STOCK PRICE($664.96) / TTM EPS($40.9)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.